Patent: 7,276,643
✉ Email this page to a colleague
Summary for Patent: 7,276,643
Title: | Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents |
Abstract: | The methodologies of the present invention demonstrate that a critical balance between pro- and anti-amyloidogenic molecules exists that regulates amyloid formation and cell death in Alzheimer\'s disease and Parkinson\'s disease. .beta.-Synuclein, the non-amyloidogenic homologue of .alpha.-synuclein, is a negative modulator of .alpha.-synuclein and A.beta. aggregation, having neuroprotective properties against .alpha.-synuclein and A.beta. neurotoxicity and that .beta.-synuclein and therapeutic agents derived therefrom block amyloidogenesis and neurodegeneration in vivo. The method of the present invention establishes that .beta.-synuclein blocks A.beta. aggregation either by direct inhibition of A.beta. amyloidogenesis or indirectly via either .alpha.-synuclein or its 35 a.a. NAC region, inferring neuroprotective characteristics within the effected cells. The generation of a transgenic mouse line and a cell system overexpressing .alpha.-synuclein characterizes the mechanisms by which .beta.-synuclein blocks .alpha.-synuclein and A.beta. aggregation and that this mechanism offers protection to the cell against amyloid formation as seen in the pathologies of Alzheimer\'s disease and Parkinson\'s disease. |
Inventor(s): | Masliah; Eliezer (San Diego, CA), Rockenstein; Edward (Chula Vista, CA), Mallory, legal representative; Hersey (Encinitas, CA), Mallory, deceased; Margaret (Encinitas, CA) |
Assignee: | The Regents of the University of California (Oakland, CA) |
Application Number: | 10/204,337 |
Patent Claims: | see list of patent claims |
Details for Patent 7,276,643
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2020-02-18 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2020-02-18 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2020-02-18 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |